Abstract
Background Policy decisions should be evidence-based, but the magnitude of intended and unintended impacts cannot always be easily estimated from the available data. For example, banning flavours in electronic cigarettes (e-cigarettes) to reduce appeal to non-smoking young people could have the intended impact by reducing youth vaping but could have negative consequences for adult smokers and vapers.
Methods We developed a decision aid to help policymakers make informed decisions on the potential net impact of a ban on e-cigarette flavours. We estimated the number of non-smoking youth who would be deterred from ever vaping and subsequently ever smoking, and the number of smokers and ex-smokers who would be deterred from quitting or encouraged to relapse, to determine whether the benefits to youth outweigh the costs to existing smokers and vapers. This aid then outputs a report with the results graphically depicted to aid interpretability.
Results We demonstrated the value of this decision aid using data from various sources to estimate the impact of a flavour ban in three populations: the general UK population, low-socioeconomic position UK population, and the general US population. All three examples suggested a negative net population impact of a ban. These reports were then presented to the all-party parliamentary group for vaping.
Conclusions We demonstrate how decision aids can be used to help policymakers arrive at evidence-based decisions efficiently and can be used to quickly obtain up-to-date estimates as new data becomes available.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was originally supported by Public Health England (PHE) via an honorary contract awarded to ASA. There is no grant number for this research as it was commissioned by Public Health England via the honorary academic framework. Further support was received from the University of Bristol via an Economic and Social Research Council Impact Acceleration Award (A100111) awarded to JNK, ASA and MRM. MJG and MRM are supported by the Medical Research Council Integrative Epidemiology Unit (MC_UU_00011/7). JNK is supported by a Cancer Research UK programme grant (the Integrative Cancer Epidemiology Programme C18281/A29019).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethical approval for the Smoking Toolkit Study was granted by the UCL ethics committee (ID 0498/001). All other data was publically available.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
In this revision, an error in the analysis code has been corrected. This has lead to changes in the results but the conclusions remain the same.
Data Availability
All data sources are outlined in the supplementary tables (with links) and are public or available upon request.
